This startup develops an AI drug discovery platform that identifies molecular endotypes from patient sub-phenotypes using multi-omics and EMR data. Their platform, Excavate, translates these insights into interactome-scale disease modules to enable targeted therapy development for specific patient populations.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug discovery processes struggle with diseases exhibiting high patient variability, leading to challenges in identifying effective therapies for specific subgroups. Existing methods often fail to account for the underlying biological differences that drive variable treatment responses. This results in increased time and cost in bringing new therapies to market.
Solution
Biossil is developing targeted therapies for biologically defined patient subgroups by leveraging an AI-driven drug discovery platform. The platform identifies molecular endotypes from patient sub-phenotypes using multi-omics data and electronic medical records (EMR). Biossil translates these insights into interactome-scale disease modules, enabling the development of therapies tailored to specific patient populations. By augmenting in silico analysis with expert interpretation, trial reanalysis, and focused preclinical experiments, Biossil aims to compress the time and cost required to bring new therapies to market.
Target Audience
The primary target audience includes patients with diseases exhibiting high variability and unmet medical needs, as well as pharmaceutical companies seeking to develop targeted therapies for specific patient subgroups.
Features
- AI-driven platform for identifying molecular endotypes from patient sub-phenotypes.
- Utilizes multi-omics data and EMR to define biologically distinct subgroups.
- Translates insights into interactome-scale disease modules for targeted therapy development.
- Broad and diversified pipeline of first-in-class assets for diseases with high unmet need and significant patient variability.
- Focus on diseases for which traditional drug discovery has been challenged by population variability.